StimuSIL Presents at Octane’s Aesthetics Tech Forum 2023 

Delaware, US, January 28th, 2023 

StimuSIL presented at Octane’s Aesthetics Tech Forum on January 26th and 27th, 2023 in Newport Beach, California. 

Octane recently celebrated its 20th year supporting various types of technological innovations. Octane’s Aesthetics Tech Forum is one of six signature industry events hosted annually for investors and industry partners. The conference featured keynote presentations, panel discussions, and networking opportunities that allow attendees to connect with industry leaders and experts in order to discuss emerging trends and technologies in the aesthetic and med-tech sectors. 

“We were honored to have been selected to present at Octane’s Aesthetic Tech Forum and very excited to share our new hair regrowth system,” said Ana Villalba, Founder and Chief Executive Officer of StimuSIL.With the growing demand for effective, non-invasive hair loss treatments, we see a huge opportunity to meet the needs of men and women with androgenetic alopecia and drive innovation in this space.”

Octane has supported the growth of over 1,500 companies via the LaunchPad SBDC accelerator, with companies receiving more than $2.85 billion in investment and equity exits. This year, StimuSIL presented at Octane’s Aesthetics Tech Forum LaunchPad alongside RealizeMD, Yuva Biosciences, Inc., Lumisque, Syntr Health Technologies, Spiderwort, and Tissue Form.

StimuSIL’s hair regrowth system is a 20-minute lunchtime procedure designed for clinical success. They aim to be one of the most effective clinic-based treatments for hair loss, offering users an alternative to hair transplantation procedures like follicular unit excision (FUE) and follicular unit transplantation (FUT). Pablo Villalba, Founder and Chairman of StimuSIL, received great feedback following StimuSIL’s product demonstration and his talk at the forum’s LaunchPad Presentations, with a number of aesthetics industry professionals requesting for their clinics to be able to participate in the product launch.  

“We believe that our hair regrowth system has the potential to revolutionize the industry,” Pablo Villalba said in an interview. “And we are eager to connect with like-minded companies and individuals who share our passion for innovation.” 

StimuSIL Welcomes New Engineers to Growing Team

Delaware, US, March 31st, 2022 

StimuSIL is excited to announce the addition of two new engineers, Dr. Siddhi Camila Lama and Guillermo Cantalapiedra Pro, to its growing team of talented professionals. As the startup continues to expand and evolve, these new team members will bring valuable skills and experience to the startup.

Guillermo Cantalapiedra Pro is joining StimuSIL as the new Vice President of Systems Development. With degrees in Electronic Systems Engineering and Industrial Engineering, and 6 years of experience working as an electronics designer, technology consultant, and engineering teacher, Cantalapiedra’s multifaceted background is a major asset to StimuSIL. His skills in product design and iterative development will play a major role in pushing the company forward. 

Five years after the launch of her science communications start-up, Palavras Deslumbrantes, Dr. Siddhi Camila Lama’s focus has returned to biomedical engineering. With more than a decade of experience in biomedical research and science communications, and degrees in Bioengineering, Organ, Tissue, and Cellular Transplantation, and Human Development, Dr. Lama will bring a wealth of knowledge and expertise to StimuSIL. Her bioengineering and materials science skills will be particularly instrumental in her role as a Postdoctoral Researcher.

“We are thrilled to have Siddhi and Guillermo join our team,” said Ana Villalba, Founder and Chief Executive Officer of StimuSIL. “Guillermo’s technical skills in electronics design and engineering and Siddhi’s expertise in both communications and biomedical device development make both of them a perfect fit for StimuSIL’s vision. We are confident that they will make significant contributions to our team and help us continue to innovate and grow.” 

“In his new role, Cantalapiedra will work closely with Chief Technical Officer Juan Mazzuchelli, who he’s previously collaborated with on automated farming and home appliances projects.” His work will be vital in shaping the company’s engineering department and is certain to make a meaningful impact in the electronic design and development of StimuSIL’s novel devices. “I am thrilled to join StimuSIL and to have the opportunity to work with Juan again,” said Cantalapiedra. “It’s very exciting to have the opportunity to work with such a talented and dedicated team. I am keen to bring my skills and experience to the table to help StimuSIL achieve its ambitious goals.”

With her diverse background in biomedical research, engineering, and communications, Dr. Lama is an all-rounder who will be collaborating with the Engineering, Marketing, R&D, and Medical Teams. “It’s wonderful to have the opportunity to work in R&D with such a passionate and talented international team,” Dr. Lama said. “I’m excited to use my expertise in biomedicine and bioengineering, and I look forward to contributing to StimuSIL’s success.”

StimuSIL Launches With a Strategic Investment by GEN

Delaware, US, and Ankara, Turkey, December 22nd, 2021 

StimuSIL, Inc. (“StimuSIL”), a preclinical stage aesthetics company developing proprietary patented methods for photobiomodulation, today announced the closing of financing led by GEN İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (“GEN”), a publicly-traded company (IST: GENIL), and leading specialty pharmaceutical company in Turkey. In addition to GEN’s investment, StimuSIL and GEN are entering into an exclusive distribution agreement that grants GEN rights to commercialize StimuSIL’s products in Turkey, the member countries of the Commonwealth of Independent States (“CIS”) including Russia, and the countries in the Middle East and North Africa (“MENA”). 

Under this collaboration, StimuSIL will continue the development of its lead candidate for androgenetic alopecia (AGA), the most common type of hair loss, for which FDA Approval and CE Marking are expected by 2024. 

“This strategic agreement with GEN provides us with an opportunity to work with a partner that has deep development and commercial expertise and shares our focus in pursuing novel treatments for patients with conditions where there are few effective options”, said Ana Villalba of StimuSIL. “We are excited to collaborate with GEN to advance our hair loss  treatment and to further demonstrate the potential of our platform for other aesthetic indications.” 

“We are proud of our reputation as one of Turkey’s leading specialty pharmaceutical and medical companies and are excited by the partnership with StimuSIL. By investing in promising high technology companies, we aim to bring innovative medicines and novel medical devices to patients in various countries in the fastest and most reliable way possible. For this purpose, we also commit to supporting StimuSIL’s research and development studies for its groundbreaking subdermal illumination with laser technology platform.” said Abidin Gülmüş, Chairman of GEN.

About GEN

GEN is the leading specialty pharmaceutical company in Turkey, with more than 20 years of experience. The company partners with global pharmaceutical companies to bring innovative therapies and rare solutions to the Turkish community. It’s compliant with ethical and scientific principles and strives to set the best standards for quality, safety, and value in the manufacture, production, and distribution of health care products. With its GMP-certified production facility and R&D center based in Ankara, it offers solutions around the globe in the treatment of rare diseases and disorders. In addition to its HQ and offices in Turkey, GEN has a branch in Germany, and representative offices in Russia, Kazakhstan, Uzbekistan, and Azerbaijan.